Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.
30d signal volume
Look up signals and intelligence for any entity
30d signal volume
Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.
Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.